Pomegranate and Hemodialysis Pilot Trial (POM Pilot)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In this study, the investigators will administer pomegranate juice or fruit extract as a targeted antioxidant therapy to hemodialysis patients.
The investigators will examine whether these pomegranate products will be safe and well-tolerated. The investigators will also examine whether these products may lead to improvements in blood serum biomarkers of:
- oxidative stress status
- inflammatory status
- endothelial dysfunction
| Condition | Intervention |
|---|---|
|
End Stage Renal Disease Cardiovascular Disease Inflammation |
Other: Pomegranate juice Other: Pomegranate fruit extract |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | A Pilot Trial Assessing the Effect of Pomegranate Juice and Extract on Biomarkers of Oxidative Stress, Systemic Inflammation, and Monocyte Function in Hemodialysis Patients |
- Markers of oxidative stress [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]Oxidative stress: F2-isoprostanes, polyphenols and lipid soluble antioxidants
- Markers of inflammation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]Inflammation: C-reactive protein, Interleukin-6, and white blood cell count
- Markers of endothelial function [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]Endothelial function: Monocyte functional assays (cytokines and other proteins), Pulse amplitude tonometry
- Number of subjects with adverse events and type of event [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Advere reactions to pomegranate juice
Adverse reactions to pomegrantate fruit extract
| Estimated Enrollment: | 30 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Pomegranate fruit extract |
Other: Pomegranate fruit extract
Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
Other Name: Clinical Active POMxp
|
| Active Comparator: Pomegranate juice |
Other: Pomegranate juice
Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
Other Name: Research Juice 100%
|
Detailed Description:
There are currently more than 400,000 patients receiving chronic dialysis therapy in the United States. Cardiovascular and infectious diseases are the leading causes of death in hemodialysis patients, accounting for over 50% of all-cause mortality.
There is a complex interaction of inflammation, oxidative stress, and endothelial dysfunction in contributing to cardiovascular and infectious risk in dialysis patients. Since there is much evidence that an increase in oxidative stress contributes to risk of disease in dialysis patients, it is logical to hypothesize the antioxidant therapy may be beneficial in reducing these risks.
In addition to vitamins C and E, the most common and active antioxidant compounds that occur naturally in foods are flavonoids. Dietary flavonoids are highly bioavailable, and have been shown to confer antioxidant protection, inhibit platelet activation, exert vasorelaxant effects, and reduce inflammation in human studies. In animal model studies, dietary flavonoids have been shown to reduce the development of atherosclerosis. Polyphenols also have potent antibacterial, antifungal, and antiviral activities.
Pomegranate juice is a rich source of potent phenolic antioxidants, which have been demonstrated to have anti-atherogenic and vasorelaxant properties. Pomegranate derived polyphenols have also been demonstrated to inhibit platelet activation.
Although available data are limited, several studies suggest that dietary phenols may have beneficial effects in patients undergoing dialysis treatment. These include improvements in lipoprotein profiles, reductions in circulating inflammatory and oxidative stress biomarkers, reductions in infectious complications, and improvements in inflammatory biomarkers. These observations, though limited, suggest that polyphenol based supplementation strategies may be effective in reducing complications in those undergoing dialysis treatment.
In this study, the investigators will administer pomegranate juice and/or fruit extract as a targeted antioxidant therapy. The investigators will examine whether these pomegranate products will be safe and well-tolerated. The investigators will also examine whether these products may lead to improvements in biomarkers of oxidative stress status, inflammatory status, and endothelial dysfunction in hemodialysis patients.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with end-stage renal disease receiving thrice weekly hemodialysis
- Age > 18 or < 85 years
- Life expectancy greater than one year
- Ability to understand and provide informed consent for participation in the study
Exclusion Criteria:
- History of poor adherence to hemodialysis or medical regimen
- Prisoners, patients with significant mental illness, and other vulnerable populations
- AIDS (HIV seropositivity is not an exclusion criteria)
- Active malignancy excluding basal cell carcinoma of the skin
- Gastrointestinal dysfunction requiring parenteral nutrition
- History of functional kidney transplant < 6 months prior to study entry
- Anticipated live donor kidney transplant
- Patients taking vitamin E supplements > 60 IU/day, vitamin C > 150 mg/day or other antioxidant or nutritional supplements
- Incident hemodialysis patients (defined as within 30 days of dialysis initiation)
- Patients hospitalized for more than 5 days within the past 30 days.
- Patients with a history of a major atherosclerotic event (defined as combined incidence of myocardial infarction, urgent target-vessel revascularization, coronary bypass surgery, and stroke) within three months
- Pregnancy
Contacts and Locations| Contact: Lori Linke, BA, DTR | 206-616-8574 | lori.linke@nwkidney.org |
| Contact: John Kundzins, BS | 206-616-8574 | info@KRI.washington.edu |
| United States, Washington | |
| Northwest Kidney Centers | Recruiting |
| Seattle, Washington, United States, 98122 | |
| Principal Investigator: | Jonathan Himmelfarb, MD | University of Washington |
More Information
Additional Information:
No publications provided
| Responsible Party: | Jonathan Himmelfarb, Professor of Medicine, University of Washington |
| ClinicalTrials.gov Identifier: | NCT01562340 History of Changes |
| Other Study ID Numbers: | 41986-D |
| Study First Received: | March 21, 2012 |
| Last Updated: | March 22, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Washington:
|
Hemodialysis End stage renal disease Oxidative stress Inflammation |
Endothelial dysfunction Cardiovascular disease Antioxidants Flavonoids |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Inflammation Kidney Diseases Kidney Failure, Chronic |
Pathologic Processes Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency |
ClinicalTrials.gov processed this record on May 21, 2013